Drug Profile
Alomfilimab - Kymab/Sanofi
Alternative Names: KY-1044; SAR-445256Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kymab
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; Regulatory T lymphocyte inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 30 Sep 2021 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA, United Kingdom, Italy, Taiwan (Parenteral) (NCT03829501) (Kymab pipeline, September 2021)
- 30 Sep 2021 Phase-II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in Italy, Taiwan, United Kingdom, USA (Parenteral) (NCT03829501) (Kymab pipeline, September 2021)
- 04 Jun 2021 Efficacy and safety data from phase I/II trial in Solid tumours presented at 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)